STOCK TITAN

Eledon Pharmaceuticals, Inc. - $ELDN STOCK NEWS

Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: $ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eledon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eledon Pharmaceuticals's position in the market.

Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) CEO, Dr. David-Alexandre C. Gros, to present company overview and participate in panel discussion at NobleCon19 - Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on December 4, 2023. Webcast available on company website and NobleCon website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences acquisition
-
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) reported updated data from ongoing Phase 1b trial supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy. The Phase 2 BESTOW trial has also been initiated. The company also reviewed recent business highlights and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
-
Rhea-AI Summary
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) to present company overview at Jefferies London Healthcare Conference. CEO David-Alexandre C. Gros, M.D. to speak on November 16, 2023, at 8:00 a.m. GMT. Webcast registration available. Webcast replay accessible on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
conferences
Rhea-AI Summary
Eledon Pharmaceuticals reports positive results from Phase 1b trial of tegoprubart in kidney transplant patients. The drug demonstrated safety, tolerability, and potential to protect organ function. No cases of hyperglycemia, new onset diabetes, tremor, or cytomegalovirus infection were reported. Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
-
Rhea-AI Summary
Eledon Pharmaceuticals appoints Dr. Eliezer Katz as Chief Medical Officer to lead clinical development programs for transplantation procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences clinical trial
Rhea-AI Summary
Eledon Pharmaceuticals appoints Dr. Allan Douglas Kirk to its Board of Directors. Dr. Kirk's expertise in organ transplantation, specifically kidney transplants, will be valuable for the company's Phase 2 BESTOW trial. Eledon aims to fulfill the unmet need for better immunosuppression regimens in transplant patients. Dr. Kirk's experience in co-stimulation pathway blockade is noteworthy. No concrete business takes affecting stock price are mentioned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.14%
Tags
management
-
Rhea-AI Summary
Eledon Pharmaceuticals announces successful xenotransplantation procedure using tegoprubart anti-CD40 antibody
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Eledon Pharmaceuticals to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences
Rhea-AI Summary
Eledon Pharmaceuticals appoints James Robinson to its Board of Directors, a seasoned biopharmaceutical executive with over 30 years of experience. Robinson's experience and expertise will be invaluable in Eledon's mission to bring a new treatment option for kidney transplantation. Robinson has a successful track record in the industry, including leading operations that generated over $1 billion in revenue. His appointment comes at a pivotal time for Eledon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
management
Eledon Pharmaceuticals, Inc.

Nasdaq:ELDN

ELDN Rankings

ELDN Stock Data

57.32M
18.02M
5.43%
38.76%
0.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
IRVINE

About ELDN

eledon pharmaceuticals, inc. is a clinical stage biotechnology company using its expertise in targeting the cd40l pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. our lead program, at-1501, is a potential best-in-class humanized igg1 anti-cd40l antibody with high affinity for cd40l, a well-validated biological target with broad therapeutic potential. the cd40/cd40l pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.